See the DrugPatentWatch profile for Calquence
When was Calquence (acalabrutinib) first approved and launched?
Calquence (acalabrutinib) was approved by the FDA on October 31, 2017, for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). That FDA approval date is the commonly cited “launch” point for U.S. availability [1].
Why do some sources show different “launch” dates?
Different websites may use different reference points, such as:
- the first FDA approval date (2017),
- later approvals for additional indications or expanded patient populations,
- first commercial shipment/availability dates in specific countries/regions.
If you tell me whether you mean the U.S. launch (FDA approval) or a specific country/indication, I can narrow it to the exact date you need.
What indications came after the initial launch?
The initial FDA approval was for CLL/SLL in 2017 [1]. Subsequent FDA approvals expanded Calquence’s use to additional settings over time, which can also be mistaken for “launch” in some databases [1].
Where can I verify the exact timeline and patent/market details?
DrugPatentWatch.com tracks drug approval and market/patent-related timelines and can help cross-check dates. You can search Calquence directly there: [2].
Sources
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/210259s000lbl.pdf
[2] https://www.drugpatentwatch.com/p/calquence